Search results
Results From The WOW.Com Content Network
Sodium channel blockers are also used as local anesthetics and anticonvulsants. [5] Sodium channel blockers have been proposed for use in the treatment of cystic fibrosis, [6] but current evidence is mixed. [7] It has been suggested that the analgesic effects of some antidepressants may be mediated in part via sodium channel blockade. [8]
In Canada, nabiximols has been approved by Health Canada for the treatment of MS spasticity. It has also received a licence with conditions (NOC/c) for two additional uses: as adjunctive treatment for the symptomatic relief of neuropathic pain in multiple sclerosis, [12] and also for pain due to cancer. [13] [14]
[1] [2] Cannabidiol (CBD), a naturally occurring cannabinoid and a non-competitive CB 1 /CB 2 receptor antagonist, as well as Δ 9-tetrahydrocannabivarin (THCV), a naturally occurring cannabinoid, modulate the effects of THC via direct blockade of cannabinoid CB 1 receptors, thus behaving like first-generation CB 1 receptor inverse agonists ...
The number of active chemicals in cannabis is one reason why treatment with cannabis is difficult to classify and study. [ 15 ] A 2014 review stated that the variations in ratio of CBD-to-THC in botanical and pharmaceutical preparations determines the therapeutic vs psychoactive effects (CBD attenuates THC's psychoactive effects [ 16 ] ) of ...
DSP-2230 is a selective small-molecule Na v 1.7 and Na v 1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain. [1] [2] As of June 2014, it is in phase I/phase II clinical trials. [1] [2]
Laboratory evidence indicated that cannabidiol may reduce THC clearance, increasing plasma concentrations which may raise THC availability to receptors and enhance its effect in a dose-dependent manner. [58] [59] In vitro, cannabidiol inhibited the activity of voltage-dependent sodium and potassium channels, which may affect neural activity. [60]
Rufinamide was approved by the US Food and Drug Administration (FDA) in November 2008, as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children four years and older and adults. Its official FDA-approved labeling does not mention use in the treatment of partial seizures inasmuch as clinical trials submitted to the ...
Cenobamate is a voltage-gated sodium channel (VGSC) blocker. [15] It is a selective blocker of the inactivated state of VGSCs, preferentially inhibiting persistent sodium current. [15] It has been proposed that cenobamate additionally enhances presynaptic release of γ-aminobutyric acid (GABA), thereby increasing inhibitory GABAergic ...